TY - JOUR
T1 - Health care access and use among adults with diabetes during the COVID-19 pandemic - United States, February-March 2021
AU - Czeisler, Mark
AU - Barrett, Catherine E.
AU - Siegel, Karen R.
AU - Weaver, Matthew D.
AU - Czeisler, Charles A.
AU - Rajaratnam, Shantha M.W.
AU - Howard, Mark E.
AU - Bullard, Kai Mc Keever
N1 - Funding Information:
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Matthew D. Weaver reports institutional support to Monash University from WHOOP, Inc., institutional grant support from the National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), the National Institute of Occupational Safety and Health (NIOSH), and consulting fees from the National Sleep Foundation and the University of Pittsburgh, outside the current work. Shantha M.W. Rajaratnam reports institutional grant support to Monash University from WHOOP, Inc. and the Cooperative Research Centre for Alertness, Safety, and Productivity; and institutional consultancy fees from Teva Pharma, Australia, Circadian Therapeutics, Vanda Pharmaceuticals, BHP Billiton, and Herbert Smith Freehills; and honoraria from Cooperative Research Centre for Alertness, Safety, and Productivity. Mark E. Howard reports an institutional grant to Monash University from WHOOP, Inc. Mark É. Czeisler reports institutional grants paid to Monash University from WHOOP, Inc. and the CDC Foundation, with funding provided by BNY Mellon, and support from the Australian-American Fulbright Foundation, with funding provided by The Kinghorn Foundation, and consulting fees from Vanda Pharmaceuticals (September 2019–January 2020). Charles A. Czeisler reports institutional support from WHOOP, Inc., and serves as the incumbent of an endowed professorship provided to Harvard Medical School by Cephalon, Inc. in 2004; grant support from Delta Airlines, Jazz Pharmaceuticals PLC, Inc., Philips Respironics, Inc., Puget Sound Pilots, Regeneron Pharmaceuticals and Sanofi SA, ResMed, Teva Pharmaceuticals Industries, Ltd, and Vanda Pharmaceuticals; royalty payments from Philips Respironics, Inc. for the Actiwatch-2 and Actiwatch-spectrum devices; personal consultancy fees from Physician’s Seal, State of Washington Board of Pilotage Commissioners, With Deep, and Vanda Pharmaceuticals; lecture fees from Teva Pharma Australia and Tencent Holdings, Ltd, and payment as Chair for the Sleep Timing and Variability Consensus Panel, National Sleep Foundation; payment for expert testimony from Aegis Chemical Solutions, Amtrak, Casper Sleep, Inc., C&J Energy Services, Enterprise Rent-A-Car, Dallas Police Association, FedEx, PAR Electrical Contractors, Inc., Puget Sound Pilots, Schlumberger Technology Corp., Union Pacific Railroad, United Parcel Service and Vanda Pharmaceuticals; travel support from Tencent Holdings, Ltd., Aspen Brain Institute, Bloomage International Investment Group, Inc., Stanley Ho Medical Development Foundation, German National Academy of Sciences, the National Safety Council, and the National Sleep Foundation; member of the following advisory boards: AARP, Institute of Digital Media and Child Development, Klarman Family Foundation, and U.K. Biotechnology and Biological Sciences Research Council; equity interest in Vanda Pharmaceuticals; and institutional educational gifts from Johnson & Johnson, Harmony Biosciences, LLC, and Philips Respironics, Inc., ResMed, and Vanda Pharmaceuticals to Brigham and Women’s Hospital. No other potential conflicts of interest were disclosed.
Publisher Copyright:
© 2021 Department of Health and Human Services. All rights reserved.
PY - 2021/11
Y1 - 2021/11
N2 - What is already known about this topic? Persons with diabetes are at high risk for severe COVID-19, and the COVID-19 pandemic has affected diabetes care and management in the United States. What is added by this report? Among adults with diabetes, those aged 18-29 years reported the most disruption in access to and use of medical care and the least engagement in prevention of COVID-19, including vaccination intent. What are the implications for public health practice? Efforts are warranted to enhance access to diabetes care during the COVID-19 pandemic, and to deliver public health messages emphasizing the importance of diabetes management and COVID-19 prevention, including vaccination, especially among younger adults with diabetes.
AB - What is already known about this topic? Persons with diabetes are at high risk for severe COVID-19, and the COVID-19 pandemic has affected diabetes care and management in the United States. What is added by this report? Among adults with diabetes, those aged 18-29 years reported the most disruption in access to and use of medical care and the least engagement in prevention of COVID-19, including vaccination intent. What are the implications for public health practice? Efforts are warranted to enhance access to diabetes care during the COVID-19 pandemic, and to deliver public health messages emphasizing the importance of diabetes management and COVID-19 prevention, including vaccination, especially among younger adults with diabetes.
UR - http://www.scopus.com/inward/record.url?scp=85120822043&partnerID=8YFLogxK
U2 - 10.15585/MMWR.MM7046A2
DO - 10.15585/MMWR.MM7046A2
M3 - Article
C2 - 34793416
AN - SCOPUS:85120822043
SN - 0149-2195
VL - 70
SP - 1597
EP - 1602
JO - Morbidity and Mortality Weekly Report
JF - Morbidity and Mortality Weekly Report
IS - 46
ER -
